Recent Updates
Recently added Catalysts
GILD Positive Sentiment

Gilead Sciences Announces Second Quarter 2026 Financial Results

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Gilead Sciences reported a strong second quarter for 2026, achieving a 10% year-over-year revenue growth primarily driven by its HIV portfolio, Trodelvy, and Livdelzi. The company noted a 12% increase in HIV sales, which reflects ongoing strength in treatment and growth in its PrEP business. This performance has led to an upward revision of revenue expectations for the year.

Market Sentiment Analysis

POSITIVE FACTORS

  • 10% year-over-year revenue growth in base business
  • Strong performance driven by HIV portfolio, Trodelvy, and Livdelzi
  • 12% growth in HIV sales
  • Increased revenue expectations for 2026

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Ranolazine
Phase 3 · Myocardial Ischemia

Full Press Release Details

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. “Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026,” said Dan

Frequently Asked Questions

What were Gilead's revenue growth figures for Q2 2026?

Gilead Sciences reported a 10% year-over-year revenue growth for Q2 2026.

What drove Gilead's revenue growth in Q2 2026?

The revenue growth was primarily driven by Gilead's HIV portfolio, Trodelvy, and Livdelzi.

How much did HIV sales grow in Q2 2026?

HIV sales grew by 12% in Q2 2026.

What are Gilead's expectations for 2026 revenue?

Gilead has increased its base business revenue expectations for 2026.

ShareAdd on Google
Tags: GILD Viatris Investor Conferences Healthcare Gilead Sciences Q2 2026 HIV sales Trodelvy
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$7628M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RanolazinePhase 3
Myocardial Ischemia →

Catalyst track record

+15%
best trade around GILD's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for GILD.

See every catalyst's timing & PoA →